ESMO 2026 Data Continue to Shine a Spotlight on Daraxonrasib’s Activity in Pretreated Metastatic Pancreatic Cancer

Welcome to OncLive On Air®! I'm your host today, Sid Rastogi.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today's episode, we spoke with Zev A. Wainberg, MD, MSc, about subgroup data from the phase 3 RASolute 302 trial (NCT06625320) of daraxonrasib (Rasonque) in patients with previously treated metastatic pancreatic cancer, which were presented at the 2026 ESMO Congress.Dr Wainberg is a professor of medicine at the David Geffen School of Medicine at UCLA and co-director of the UCLA GI Oncology Program in Los Angeles, California.

In our exclusive interview, Dr Wainberg discussed how daraxonrasib improved overall survival (OS) vs investigator’s choice of standard-of-care chemotherapy across RAS genotype subgroups, preselected chemotherapy regimens, and prior treatment settings. Additionally, Dr Wainberg shared practical advice for managing rash and stomatitis, including treatment holds and dose reductions. Finally, Dr Wainberg explained how RAS(ON) inhibition is moving into earlier lines of therapy and why he supports genomic testing at diagnosis.

Dr Wainberg presented the analyses at the 2026 ESMO Congress on behalf of the RASolute 302 investigators. The trial randomly assigned 500 patients with metastatic pancreatic adenocarcinoma who had received 1 prior fluoropyrimidine- or gemcitabine-based regimen in the metastatic setting to daraxonrasib at 300 mg once daily (n = 248) or investigator’s choice of chemotherapy (n = 252). In the primary analysis, daraxonrasib generated a median OS of 13.2 months (95% CI, 10.0-not estimable) vs 6.7 months (95% CI, 5.8-8.0) with chemotherapy (HR, 0.40; 95% CI, 0.30-0.53; P = 4.6 × 10^–11).

Dr Wainberg first addressed the subgroup findings by RAS genotype. RAS G12D and G12V mutations predominated, accounting for 43.2% and 35.6% of the study population, respectively, and Dr Wainberg noted that nearly every genotype subgroup favored daraxonrasib for OS. The OS HRs were 0.49 (95% CI, 0.33-0.74) in the G12D subgroup (n = 95 vs 121), 0.32 (95% CI, 0.19-0.54) in the G12V subgroup (n = 102 vs 76), 0.61 (95% CI, 0.29-1.30) in the G12R subgroup (n = 30 vs 31), and 0.43 (95% CI, 0.09-1.98) in patients with no RAS mutation identified (n = 9 vs 7).

Turning to sequencing, Dr Wainberg explained that neither the first-line regimen nor the chemotherapy selected for the control arm appeared to change the benefit of daraxonrasib. The OS HR was 0.45 (95% CI, 0.32-0.65) when gemcitabine plus nab-paclitaxel (Abraxane) was the preselected comparator (n = 140 vs 141), 0.46 (95% CI, 0.23-0.95) for pooled modified FOLFIRINOX or FOLFOX (n = 30 vs 30), and 0.32 (95% CI, 0.18-0.58) for nanoliposomal irinotecan (Onivyde) plus 5-fluorouracil and leucovorin (n = 78 vs 81).

Looking ahead, Dr Wainberg noted that trials of RAS(ON) inhibition are already enrolling in the adjuvant and first-line settings, and that many KRAS inhibitors presented at the meeting are moving quickly to phase 3 studies.

That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.